Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis.

ABSTRACT:

Backgound

Little information regarding to the survival advantage of third-line chemotherapy in advanced gastric cancer patients is available. The current study is designed to systematically review and perform meta-analysis on the effect of third-line chemotherapy on progressive or recurrent gastric cancer treatment.

Methods

After thorough searching of online databases, total 20 articles were included into qualitative systematic review and 6 of them were used to conduct qualitative meta-analysis.

Results

It was found that the third-line chemotherapy was superior to placebo or best supportive care in terms of prolonging median oval survival (OS) length and progress free survival (PFS) length (Hedges's g for OS = -0.315 ± 0.077, P < .001; and for PFS = -0.382 ± 0.098, P 

SUBMITTER: Zheng Y 

PROVIDER: S-EPMC5478304 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature